Aveanna Expects ‘Zero Impact’ From Home Health Moratorium

Why It Matters

The moratorium leaves Aveanna’s growth trajectory and cash‑flow outlook intact, reassuring investors while underscoring regulatory risk for competitors reliant on Medicare enrollment. Its acquisition and payer‑expansion plans position the firm to capture more private‑pay and preferred‑payer business amid a stable reimbursement environment.

Key Takeaways

• Aveanna’s $175.5M Family First Homecare deal slated for late Q2
• CMS moratorium won’t affect Aveanna’s Q1 earnings or growth outlook
• Company targets 38 preferred payer agreements by 2026, 8 added this year
• Q1 revenue rose 15.9% to $647.9M; EBITDA up 25.2% YoY
• Aveanna aims for mid‑single‑digit state rate hikes in 2026

Pulse Analysis

The Centers for Medicare & Medicaid Services (CMS) recently imposed a six‑month moratorium on new enrollments for home health and hospice agencies, aiming to curb fraud in high‑risk regions. While the pause addresses systemic abuse, it also creates uncertainty for providers that depend heavily on Medicare referrals. Aveanna Healthcare, a leading pediatric and adult home‑care provider, publicly stated that the moratorium will not affect its current operations or financial targets, signaling confidence in its diversified payer mix and robust cash flow.

Aveanna’s strategic focus remains on expanding its service footprint through both organic growth and targeted acquisitions. The pending $175.5 million purchase of Family First Homecare will broaden its presence in the home‑health market and complement its existing pediatric‑care strengths. The company also pursued a disciplined M&A approach, earmarking free cash flow for smaller tuck‑in deals rather than large, transformative transactions. Concurrently, Aveanna accelerated its preferred‑payer strategy, securing four new private‑duty agreements in Q1 and aiming for a total of 38 by 2026, which should stabilize revenue streams and improve margin resilience.

Financially, Aveanna delivered a strong first‑quarter performance, with revenue climbing 15.9% to $647.9 million and adjusted EBITDA rising 25.2% year‑over‑year to $84.4 million. The firm lifted its full‑year revenue outlook to $2.56‑$2.58 billion, reflecting confidence in continued demand and favorable rate adjustments. Analysts view the company’s ability to achieve mid‑single‑digit state rate enhancements and its focus on cost‑of‑living wage adjustments as positive signs for long‑term profitability, especially as rural providers grapple with the enrollment freeze.